Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | OXER1 | Q8TDS5 | 2/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10066950 | 0.82 | CYP2A6 (0.44) | DRD2DRD3RORCBRPF1ENPP3 | |
| SCHEMBL3699735 | 0.78 | OXER1 (0.54) | GPR84OXER1 | |
| SCHEMBL28870713 | 0.78 | BRPF1 (0.45) | TSHRGPR84PLA2G4ABRPF1OXER1 | |
| SCHEMBL287263 | 0.78 | OXER1 (0.54) | GPR84OXER1 | |
| SCHEMBL7443481 | 0.78 | RORC (0.45) | RORCBRPF1ENPP3CDC7 | |
| SCHEMBL30282852 | 0.78 | TLR8 (0.44) | GPR84RORCPLA2G4AOXER1 | |
| SCHEMBL19329672 | 0.77 | CYP19A1 (0.38) | TSHRHSD17B10CYP19A1CDC7 | |
| SCHEMBL19329643 | 0.77 | CYP19A1 (0.38) | TSHRHSD17B10CYP19A1CDC7 | |
| SCHEMBL28283584 | 0.77 | BRPF1 (0.46) | GPR84PLA2G4ABRPF1OXER1 | |
| SCHEMBL3696937 | 0.76 | OXER1 (0.54) | GPR84OXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION | 2011-11-10 | — | — | US | disclosed |
| WO-2010033701-A2 | INHIBITORS OF SPHINGOSINE KINASE 1 | GENZYME CORPORATION (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275673-A1 | INHIBITORS OF SPHINGOSINE KINASE 1 | SPHK1, SPHK2, S1PR1 | TSHR 3295/4885HSD17B10 914/4885DRD2 4732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.